Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Interim Analysis Results from Pfizer's (PFE) Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

Source Link:: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_interim_analysis_results_from_phase_3_beacon_crc_trial_of_braftovi_encorafenib_mektovi_binimetinib_and_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PFE

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data The BRAFTOVI Triplet showed a median OS of 9.0 months for patients treated with the Triplet, compared to 5.4 months for Control ([HR 0.52, (95% CI 0.39-0.70), p<0.0001]). The BRAFTOVI Triplet also demonstrated a significantly improved ORR of 26% (95% CI: 18%, 35%) compared to 2% (95% CI: 0%, 7%) for Control (p<0.0001).

https://www.pfizer.c...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 30, 2019

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Mektovi, Encorafenib, Braftovi, Phase 3 Study, Binimetinib, Colorectal Cancer